thymodepressin | 186087-26-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: thymodepressin
• 英文别名: Orilotimod；(2R)-2-amino-5-[[(1R)-1-carboxy-2-(1H-indol-3-yl)ethyl]amino]-5-oxopentanoic acid
• CAS: 186087-26-3
• 化学式: C₁₆H₁₉N₃O₅
• 分子量: 333.344
• InChiKey: CATMPQFFVNKDEY-DGCLKSJQSA-N

物化性质

• 沸点：
  737.3±60.0 °C(Predicted)
• 密度：
  1.428±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -2.7
• 重原子数：
  24
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  146
• 氢给体数：
  5
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  thymodepressin 在 magnesium hydroxide 、 ammonium hydroxide 作用下， 以 水 为溶剂， 反应 3.0h， 生成 D-isoglutamyl-D-tryptophan magnesium salt
  参考文献：
  名称：

  PHARMACEUTICALLY ACCEPTABLE SALTS OF THYMODEPRESSIN AND PROCESSES FOR THEIR MANUFACTURE

  摘要：

  本发明涉及D-异谷氨酰-D-色氨酸的药用可接受的结晶盐和非晶盐，以及其制备过程、包含它们的药物组合物，以及它们在制备用于治疗各种疾病和/或疾病的药物组合物中的用途。具体来说，本发明涉及D-异谷氨酰-D-色氨酸非晶钾盐。

  公开号：

  US20150225341A1

文献信息

• [EN] PRODRUGS OF D-ISOGLUTAMYL-[D/L]-TRYPTOPHAN<br/>[FR] PROMÉDICAMENTS DE D-ISOGLUTAMYL-[D/L]-TRYPTOPHANE
  申请人：APOTEX TECHNOLOGIES INC

  公开号：WO2012129671A1

  公开（公告）日：2012-10-04

  Provided are carboxylic ester derivatives of formula (I), methods of preparing them, and methods for using them. These compounds are prodrugs of D-isoglutamyl-[D/L]-tryptophan. The in vitro bioconversion of some of the prodrugs to the parent drug D-isoglutamyl-D-tryptophan (or thymodepressin) was tested in human hepatocytes and in human blood. In vivo pharmacokinetic studies following oral administration of some of the prodrugs to rats are also reported.

  提供了公式（I）的羧酸酯衍生物，其制备方法以及使用方法。这些化合物是D-异谷氨酰-[D/L]-色氨酸的前药。对一些前药在人类肝细胞和人类血液中转化为母药D-异谷氨酰-D-色氨酸（或胸腺抑制素）的体外生物转化进行了测试。还报告了将一些前药口服给大鼠后的体内药代动力学研究。
• [EN] PRODRUGS OF D-GAMMA-GLUTAMYL-D-TRYPTOPHAN AND D-GAMMA- GLUTAMYL-L-TRYPTOPHAN<br/>[FR] PROMÉDICAMENTS DE D-GAMMA-GLUTAMYL-D-TRYPTOPHANE ET D-GAMMA-GLUTAMYL-L-TRYPTOPHANE
  申请人：APOTEX TECHNOLOGIES INC

  公开号：WO2012129680A1

  公开（公告）日：2012-10-04

  The present invention provides pro-drugs of D-gamma-glutamyl-[D/L] -tryptophan, said pro-drugs are compounds of Formula I or pharmaceutically acceptable salts thereof, wherein G is C1-C8 alkyl or benzyl, T is C1-C8 alkyl or benzyl, and * is a chiral carbon in a (R) or (S) configuration, provided that when * is in the (R) configuration, at least one of G and T is C5-C8 alkyl; and use of compounds of Formula I in a pharmaceutical composition.

  本发明提供D-γ-谷氨酰-[D/L]-色氨酸的前药，所述前药是化合物I的药用可接受盐，其中G为C1-C8烷基或苄基，T为C1-C8烷基或苄基，*为(R)或(S)构型的手性碳，但当*为(R)构型时，至少有一个G和T为C5-C8烷基；以及化合物I在制药组合物中的使用。
• CRYSTALLINE D-ISOGLUTAMYL-D-TRYPTOPHAN AND THE MONO AMMONIUM SALT OF D-ISOGLUTAMYL-D-TRYPTOPHAN
  申请人：Tam Tim Fat

  公开号：US20100016243A1

  公开（公告）日：2010-01-21

  A process for making pure crystalline D-isoglutamyl-D-tryptophan is provided which includes the step of deprotecting essentially pure N-tert-butoxycarbonyl-D-isoglutamyl-D-tryptophan or its diester to yield essentially pure D-isoglutamyl-D-tryptophan. A process is also provided for the preparation of pure mono ammonium salt of D-isoglutamyl-D-tryptophan from essentially pure N-tert-butoxycarbonyl-D-isoglutamyl-D-tryptophan. D-isoglutamyl-D-tryptophan, ammonium salt (1:1) is a stable pharmaceutical solid.

  提供了一种制备纯结晶D-异戊氨酰-D-色氨酸的过程，包括去保护基本纯的N-叔丁氧羰基-D-异戊氨酰-D-色氨酸或其二酯的步骤，以得到基本纯的D-异戊氨酰-D-色氨酸。还提供了一种从基本纯的N-叔丁氧羰基-D-异戊氨酰-D-色氨酸制备纯D-异戊氨酰-D-色氨酸单铵盐的过程。D-异戊氨酰-D-色氨酸，铵盐（1:1）是一种稳定的药用固体。
• Pharmaceutically Acceptable Salts of Thymodepressin and Processes for their Manufacture
  申请人：Tam Tim Fat

  公开号：US20100056803A1

  公开（公告）日：2010-03-04

  The present invention relates to pharmaceutically acceptable crystalline and amorphous salts of D-isoglutamyl-D-tryptophan as well as processes for their manufacture, pharmaceutical compositions comprising them, and their uses in the preparation of pharmaceutical compositions for the treatment of various conditions and/or diseases. In particular, the present invention relates to D-isoglutamyl-D-tryptophan potassium salt (1:1), D-isoglutamyl-D-tryptophan lithium salt (1:1), D-isoglutamyl-D-tryptophan calcium salt (2:1), D-isoglutamyl-D-tryptophan magnesium salt (2:1), and D-isoglutamyl-D- tryptophan organic ammonium salts (1:1).

  该发明涉及药用可接受的D-异谷氨酰-D-色氨酸的结晶和非晶盐，以及它们的制备方法、包含它们的药物组合物，以及它们在制备用于治疗各种疾病和/或疾病的药物组合物中的用途。具体而言，该发明涉及D-异谷氨酰-D-色氨酸钾盐（1:1）、D-异谷氨酰-D-色氨酸锂盐（1:1）、D-异谷氨酰-D-色氨酸钙盐（2:1）、D-异谷氨酰-D-色氨酸镁盐（2:1）和D-异谷氨酰-D-色氨酸有机铵盐（1:1）。
• CRYSTALLINE FORMS OF THE MONO-SODIUM SALT OF D-ISOGLUTAMYL-D-TRYPTOPHAN
  申请人：Tam Tim Fat

  公开号：US20100029742A1

  公开（公告）日：2010-02-04

  The present invention relates to crystalline forms of the mono-sodium salt of D-isoglutamyl-D-tryptophan, pharmaceutical compositions comprising them, their use in the treatment of various diseases and conditions, and processes for their preparation. In particular, the present invention relates the crystal modification 1 (polymorphic form F), the crystal modification 2 (polymorphic form I), and the crystal modification 3 (polymorphic form X) of the mono-sodium salt of D-isoglutamyl-D-tryptophan.

  本发明涉及D-异谷氨酰-D-色氨酸单钠盐的结晶形式，包括它们的药物组合物，它们在治疗各种疾病和病况中的应用，以及它们的制备方法。具体来说，本发明涉及D-异谷氨酰-D-色氨酸单钠盐的晶体改性1（多形式F）、晶体改性2（多形式I）和晶体改性3（多形式X）。